Updated on 30 October 2015
(Photo Courtesy: www.cog-med.com)
The global therapeutics and prophylactics market for Clostridium difficile infections (CDIs) will expand more than fourfold from $356.3 million in 2014 to over $1.5 billion by 2024, representing an impressive Compound Annual Growth Rate (CAGR) of 15.8%, according to research and consulting firm GlobalData.
The company's latest report states that this increase, which will occur across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK and Japan, will be driven by the modest uptake of patent-protected, CDI-specific antibiotics and the arrival of novel non-antibiotic approaches to treat and prevent recurrent CDI.
Dr Marc C Hansel, GlobalData's healthcare industry analyst, says that while Merck will lead the CDI treatment landscape during the forecast period, several other competitors, such as Sanofi Pasteur, Rebiotix, and Seres Health could also take a sizeable share of the market by 2024.
He comments: "We anticipates that Merck's Dificid will be the antibiotic market leader due to its first-to-market status and uncertainty over whether the current pipeline antibacterials, such as Actelion's cadazolid, Merck's surotomycin, and Summit Therapeutics' SMT19969, will provide improved clinical benefits in terms of higher initial cure rates and lower recurrence rates.
"Adjunctive therapies, such as Merck's bezlotoxumab, Seres Therapeutics' SER-109, and Rebiotix's RBX2660, will be primarily prescribed for patients at high risk of recurrence or those with multiple recurrent infections, but uptake could be limited by the high cost of these therapies."